In the latest trading session, 1.71 million Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares changed hands as the company’s beta touched 0.59. With the company’s most recent per share price at $10.86 changing hands around $0.36 or 3.48% at last look, the market valuation stands at $3.30B. IOVA’s current price is a discount, trading about -68.78% off its 52-week high of $18.33. The share price had its 52-week low at $3.21, which suggests the last value was 70.44% up since then. When we look at Iovance Biotherapeutics Inc’s average trading volume, we note the 10-day average is 9.13 million shares, with the 3-month average coming to 7.30 million.
Analysts gave the Iovance Biotherapeutics Inc (IOVA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.46. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended IOVA as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Iovance Biotherapeutics Inc’s EPS for the current quarter is expected to be -0.3.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Instantly IOVA is in green as seen in intraday trades today. With action 7.73%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 33.64%, with the 5-day performance at 7.73% in the green. However, in the 30-day time frame, Iovance Biotherapeutics Inc (NASDAQ:IOVA) is 36.49% up. Looking at the short shares, we see there were 61.32 million shares sold at short interest cover period of 9.82 days.
The consensus price target for the stock as assigned by Wall Street analysts is 23, meaning bulls need an upside of 52.78% from its recent market value. According to analyst projections, IOVA’s forecast low is 6 with 40 as the target high. To hit the forecast high, the stock’s price needs a -268.32% plunge from its current level, while the stock would need to tank 44.75% for it to hit the projected low.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Data shows that the Iovance Biotherapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 18.74% over the past 6 months, a 33.33% in annual growth rate that is considerably higher than the industry average of 18.00%. Year-over-year growth is forecast to reach 13,563.60% up from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 53.79M. 12 analysts are of the opinion that Iovance Biotherapeutics Inc’s revenue for the current quarter will be 77.18M. The company’s revenue for the corresponding quarters a year ago was 469k and 482k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 11,369.10%. The estimates for the next quarter sales put growth at 15,912.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -8.25%. The 2024 estimates are for Iovance Biotherapeutics Inc earnings to increase by 31.97%.
IOVA Dividends
Iovance Biotherapeutics Inc is expected to release its next quarterly earnings report in September.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.50% of Iovance Biotherapeutics Inc shares while 87.28% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 87.72%. There are 87.28% institutions holding the Iovance Biotherapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-03-31, the company held 9.7344% of the shares, roughly 24.92 million IOVA shares worth $369.24 million.
MHR FUND MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.3757% or 24.0 million shares worth $355.64 million as of 2024-03-31.
Among Mutual Funds, the top two as of Mar 31, 2024 were Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. With 7.9 shares estimated at $85.94 million under it, the former controlled 2.82% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 2.42% of the shares, roughly 6.77 shares worth around $73.58 million.
